MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, RARE has $1,532M in assets. $1,605M in debts. $421M in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
247.66%
Quick Ratio
234.11%
Cash Ratio
109.64%
Debt to Asset Ratio
104.77%
Assets Breakdown
    • Cash and cash equivalents
    • Property, plant and equipment, g...
    • Marketable securities
    • Others
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in capital
    • Liabilities for sales of future ...
    • Others

Unit: Million (M) dollars (except for numbers of shares and EPS)
Balance Sheets
2025-12-31
Cash and cash equivalents
421
Marketable securities
259
Accounts receivable, net
158
Inventory
52
Prepaid expenses and other assets
61
Total current assets
951
Property, plant and equipment, gross
380
Less accumulated depreciation
136
Property, plant, and equipment, net
244
Marketable securities
57
Intangible assets, net
176
Goodwill
44
Other assets
60
Total assets
1,532
Accounts payable
31
Accrued liabilities
265
Lease liabilities
12
Liabilities for sales of future royalties
69
Other liabilities
7
Total current liabilities
384
Lease liabilities
24
Deferred tax liabilities
30
Liabilities for sales of future royalties
1,147
Other liabilities
20
Total liabilities
1,605
Noncontrolling interest
7
Treasury stock, at cost, 0.2 shares in 2025 and 0.1 shares in 2024
8
Deferred compensation obligation
8
Additional paid-in capital
4,451
Accumulated other comprehensive income (loss)
1
Accumulated deficit
-4,532
Total stockholders' equity (deficit)
-80
Total liabilities, noncontrolling interest and stockholders' equity (deficit)
1,532
Unit: Million (M) dollars

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Property, plant andequipment, gross$380M Prepaid expenses andother assets$61M Inventory$52M Accounts receivable, net$158M Marketable securities$259M Cash and cashequivalents$421M Other assets$60M Goodwill$44M Intangible assets, net$176M Marketable securities$57M Property, plant, andequipment, net$244M Total current assets$951M Less accumulateddepreciation$136M Total assets$1,532M Accumulated deficit-$4,532M Treasury stock, at cost,0.2 shares in 2025...$8M Total liabilities,noncontrolling interest and...$1,532M Total stockholders'equity (deficit)-$80M Accumulated othercomprehensive income (loss)$1M Additional paid-in capital$4,451M Deferred compensationobligation$8M Noncontrolling interest$7M Total liabilities$1,605M Other liabilities$20M Liabilities for sales offuture royalties$1,147M Deferred tax liabilities$30M Lease liabilities$24M Total currentliabilities$384M Other liabilities$7M Liabilities for sales offuture royalties$69M Lease liabilities$12M Accrued liabilities$265M Accounts payable$31M

Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc. (RARE)